Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Urolithiasis
Published in: Urolithiasis 1/2011

01-02-2011 | Original Paper

An assessment of parathyroid hormone, calcitonin, 1,25 (OH)2 vitamin D3, estradiol and testosterone in men with active calcium stone disease and evaluation of its biochemical risk factors

Authors: Nasser Shakhssalim, Kobra Roohi Gilani, Mahmoud Parvin, Peyman Mohammadi Torbati, Amir H. Kashi, Mohaddeseh Azadvari, Banafsheh Golestan, Abbas Basiri

Published in: Urolithiasis | Issue 1/2011

Login to get access

Abstract

The aim of this study is to investigate the serum levels of parathyroid hormone (PTH), calcitonin, 1,25 (OH)2 vitamin D3, estradiol and testosterone in male patients with active renal calcium stone disease compared with controls and investigate their relationship with serum/urinary biochemistry. Male active renal calcium stone formers (ASF) were enrolled from December 2008 to April 2009. Controls were selected from age and sex matched individuals. Two 24-h urine samples and a blood sample were withdrawn from each participant while they were on free diet. Serum 1,25 (OH)2 vitamin D3 levels in the ASF and control groups were 127 ± 40 and 93 ± 35 pmol/l (p < 0.001). Serum levels of PTH, calcitonin, estradiol and testosterone were not statistically different between the ASF and control groups (all p > 0.05). Serum 1,25 (OH)2 vitamin D3 was associated with higher urinary excretion of calcium and phosphorus in ASF patients. Serum levels of calcitonin were related to less urinary excretion of calcium in the control group. Serum testosterone was related to higher urinary excretion of uric acid in ASF patients and to higher urinary excretion of oxalate in the control group. 1,25 (OH)2 Vitamin D3 is an important hormone in the pathogenesis of recurrent renal calcium stone disease and could increase renal stone risk by increasing the urinary excretion of calcium and phosphorus. There is a possibility of testosterone involvement in the pathogenesis of renal stones through higher urinary uric acid and oxalate excretion.
Literature
1.
Bihl G, Meyers A (2001) Recurrent renal stone disease-advances in pathogenesis and clinical management. Lancet 358:651–656CrossRefPubMed
2.
Griffin DG (2004) A review of the heritability of idiopathic nephrolithiasis. J Clin Pathol 57:793–796CrossRefPubMed
3.
Mossetti G, Rendina D, Viceconti R, Manno G, Guadagno V, Strazzullo P, Nunziata V (2004) The relationship of 3′ vitamin D receptor haplotypes to urinary supersaturation of calcium oxalate salts and to age at onset and familial prevalence of nephrolithiasis. Nephrol Dial Transplant 19:2259–2265CrossRefPubMed
4.
Relan V, Khullar M, Singh SK, Sharma SK (2004) Association of vitamin D receptor genotypes with calcium excretion in nephrolithiatic subjects in northern India. Urol Res 32:236–240CrossRefPubMed
5.
Scott P, Ouimet D, Valiquette L, Guay G, Proulx Y, Trouve ML, Gagnon B, Bonnardeaux A (1999) Suggestive evidence for a susceptibility gene near the vitamin D receptor locus in idiopathic calcium stone formation. J Am Soc Nephrol 10:1007–1013PubMed
6.
Smith LH (1987) Pathogenesis of renal stones. Miner Electrolyte Metab 13:214–219PubMed
7.
8.
Giannini S, Nobile M, Castrignano R, Pati T, Tasca A, Villi G, Pellegrini F, D’Angelo A (1993) Possible link between vitamin D and hyperoxaluria in patients with renal stone disease. Clin Sci (Lond) 84:51–54
9.
Khanam A, Rahman MA (1993) Parathyroid hormone in urinary stone patients. Mol Cell Biochem 121:1–4CrossRefPubMed
10.
von Lilienfeld-Toal H, Bach D, Hesse A, Franck H, Issa S (1982) Parathyroid hormone is normal in renal stone patients with idiopathic hypercalciuria and high fasting urinary calcium. Urol Res 10:205–207CrossRef
11.
Chen WC, Wu HC, Lu HF, Chen HY, Tsai FJ (2001) Calcitonin receptor gene polymorphism: a possible genetic marker for patients with calcium oxalate stones. Eur Urol 39:716–719CrossRefPubMed
12.
Goodman HO, Holmes RP, Assimos DG (1995) Genetic factors in calcium oxalate stone disease. J Urol 153:301–307CrossRefPubMed
13.
Shainkin-Kestenbaum R, Winikoff Y, Paran E, Lismer L (1984) The role of calcitonin in calcium stone formation. Nephron 38:154–155CrossRefPubMed
14.
Fuss M, Pepersack T, Corvilain J, Bergmann P, Simon J, Body JJ (1991) Calcitonin secretion in idiopathic renal stone formers. J Bone Miner Res 6:35–38CrossRefPubMed
15.
Jarrar K, Amasheh RA, Graef V, Weidner W (1996) Relationship between 1,25-dihydroxyvitamin-D, calcium and uric acid in urinary stone formers. Urol Int 56:16–20CrossRefPubMed
16.
Gascon-Barre M, D’Amour P, Dufresne L, Perreault JP (1985) Interrelationships between circulating vitamin D metabolites in normocalciuric and hypercalciuric renal stone formers. Ann Nutr Metab 29:289–296CrossRefPubMed
17.
Netelenbos JC, Jongen MJ, van der Vijgh WJ, Lips P, van Ginkel FC (1985) Vitamin D status in urinary calcium stone formation. Arch Intern Med 145:681–684CrossRefPubMed
18.
Ding C, Cicuttini F, Parameswaran V, Burgess J, Quinn S, Jones G (2009) Serum levels of vitamin D, sunlight exposure, and knee cartilage loss in older adults: the Tasmanian older adult cohort study. Arthritis Rheum 60:1381–1389CrossRefPubMed
19.
Hammar ML, Berg GE, Larsson L, Tiselius HG, Varenhorst E (1987) Endocrine changes and urinary citrate excretion. Scand J Urol Nephrol 21:51–53CrossRefPubMed
20.
Johnson CM, Wilson DM, O’Fallon WM, Malek RS, Kurland LT (1979) Renal stone epidemiology: a 25-year study in Rochester, Minnesota. Kidney Int 16:624–631CrossRefPubMed
21.
Dey J, Creighton A, Lindberg JS, Fuselier HA, Kok DJ, Cole FE, Hamm LL (2002) Estrogen replacement increased the citrate and calcium excretion rates in postmenopausal women with recurrent urolithiasis. J Urol 167:169–171CrossRefPubMed
22.
Heller HJ, Sakhaee K, Moe OW, Pak CY (2002) Etiological role of estrogen status in renal stone formation. J Urol 168:1923–1927CrossRefPubMed
23.
Holick MF (1995) Environmental factors that influence the cutaneous production of vitamin D. Am J Clin Nutr 61:638S–645SPubMed
24.
Group LLS (2006) Laboratory test information guide. London Health Sciences Centre, London
25.
Calatayud M, Jodar E, Sanchez R, Guadalix S, Hawkins F (2009) Prevalence of deficient and insufficient vitamin D levels in a young healthy population. Endocrinol Nutr 56:164–169CrossRefPubMed
26.
Lamberg-Allardt CJ, Outila TA, Karkkainen MU, Rita HJ, Valsta LM (2001) Vitamin D deficiency and bone health in healthy adults in Finland: could this be a concern in other parts of Europe? J Bone Miner Res 16:2066–2073CrossRefPubMed
27.
Adams ND, Gray RW, Lemann J Jr (1979) The effects of oral CaCO3 loading and dietary calcium deprivation on plasma 1,25-dihydroxyvitamin D concentrations in healthy adults. J Clin Endocrinol Metab 48:1008–1016CrossRefPubMed
28.
Erickson SB, Cooper K, Broadus AE, Smith LH, Werness PG, Binder HJ, Dobbins JW (1984) Oxalate absorption and postprandial urine supersaturation in an experimental human model of absorptive hypercalciuria. Clin Sci (Lond) 67:131–138
29.
Lindsjo M, Danielson BG, Fellstrom B, Norheim I, Wide L, Ljunghall S (1992) Parathyroid function in relation to intestinal function and renal calcium reabsorption in patients with nephrolithiasis. Scand J Urol Nephrol 26:55–64CrossRefPubMed
30.
D’Angelo A, Calo L, Cantaro S, Giannini S (1997) Calciotropic hormones and nephrolithiasis. Miner Electrolyte Metab 23:269–272PubMed
31.
McKane WR, Khosla S, Burritt MF, Kao PC, Wilson DM, Ory SJ, Riggs BL (1995) Mechanism of renal calcium conservation with estrogen replacement therapy in women in early postmenopause—a clinical research center study. J Clin Endocrinol Metab 80:3458–3464CrossRefPubMed
32.
Nordin BE, Need AG, Morris HA, Horowitz M (1999) Biochemical variables in pre- and postmenopausal women: reconciling the calcium and estrogen hypotheses. Osteoporos Int 9:351–357CrossRefPubMed
33.
Domrongkitchaiporn S, Ongphiphadhanakul B, Stitchantrakul W, Chansirikarn S, Puavilai G, Rajatanavin R (2002) Risk of calcium oxalate nephrolithiasis in postmenopausal women supplemented with calcium or combined calcium and estrogen. Maturitas 41:149–156CrossRefPubMed
34.
Mattix Kramer HJ, Grodstein F, Stampfer MJ, Curhan GC (2003) Menopause and postmenopausal hormone use and risk of incident kidney stones. J Am Soc Nephrol 14:1272–1277CrossRefPubMed
35.
Lee YH, Huang WC, Chiang H, Chen MT, Huang JK, Chang LS (1992) Determinant role of testosterone in the pathogenesis of urolithiasis in rats. J Urol 147:1134–1138PubMed
36.
Lee YH, Huang WC, Huang JK, Chang LS (1996) Testosterone enhances whereas estrogen inhibits calcium oxalate stone formation in ethylene glycol treated rats. J Urol 156:502–505CrossRefPubMed
37.
Kuczera M, Kiersztejn M, Kokot F, Klin M (1993) Behavior of sex hormone and gonadotropin secretion in men with active nephrolithiasis. Endokrynol Pol 44:539–547PubMed
38.
Fan J, Chandhoke PS, Grampsas SA (1999) Role of sex hormones in experimental calcium oxalate nephrolithiasis. J Am Soc Nephrol 10(Suppl 14):S376–380PubMed
39.
Yagisawa T, Ito F, Osaka Y, Amano H, Kobayashi C, Toma H (2001) The influence of sex hormones on renal osteopontin expression and urinary constituents in experimental urolithiasis. J Urol 166:1078–1082CrossRefPubMed
40.
Curhan GC, Willett WC, Speizer FE, Stampfer MJ (2001) Twenty-four-hour urine chemistries and the risk of kidney stones among women and men. Kidney Int 59:2290–2298PubMed
41.
Parks JH, Coe FL (1986) A urinary calcium-citrate index for the evaluation of nephrolithiasis. Kidney Int 30:85–90CrossRefPubMed
Metadata
Title
An assessment of parathyroid hormone, calcitonin, 1,25 (OH)2 vitamin D3, estradiol and testosterone in men with active calcium stone disease and evaluation of its biochemical risk factors
Authors
Nasser Shakhssalim
Kobra Roohi Gilani
Mahmoud Parvin
Peyman Mohammadi Torbati
Amir H. Kashi
Mohaddeseh Azadvari
Banafsheh Golestan
Abbas Basiri
Publication date
01-02-2011
Publisher
Springer-Verlag
Published in
Urolithiasis / Issue 1/2011
Print ISSN: 2194-7228
Electronic ISSN: 2194-7236
DOI
https://doi.org/10.1007/s00240-010-0276-3

Other articles of this Issue 1/2011

Urolithiasis 1/2011 Go to the issue

Original Paper

Effect of uropathogens on in vitro encrustation of polyurethane double J ureteral stents

Case Report

Specific management of acute renal failure caused by an upper ureteral stone in a solitary pelvic kidney

Original Paper

Lithogenic activity and clinical relevance of lipids extracted from urines and stones of nephrolithiasis patients

Original Paper

Prediction of outcome of extracorporeal shock wave lithotripsy in the management of ureteric calculi

Original Paper

Pro-inflammatory and oxidative effects of noncrystalline uric acid in human mesangial cells: contribution to hyperuricemic glomerular damage

Case Report

Antibiotics therapy was effective in preventing bilateral staghorn renal matrix stones